Search CommunityWalk:


Vaccinogen, Inc.

5300 Westview Drive, Suite 406
Frederick, MD 21703, USA

Category: Biotechnology/Biopharmaceutical - Vaccines

Used in the following map:

Maryland Biotech Industry Map

Vaccinogen, Inc. is a biotechnology company that develops and commercializes cancer vaccines and other immunotherapeutic products. It focuses on discovering, developing and manufacturing fully human monoclonal antibodies for human clinical use. It was formed in 2007 by Michael G. Hanna.

Vaccinogen's lead product, OncoVAX® vaccine is indicated for the treatment of stage II colon cancer. It is an active specific immunotherapy (ASI) that uses the patient's own cancer cells to block the return of colon cancer following surgery. This patient-specific vaccine comprises sterile, metabolically active, irradiated, non-tumorigenic autologous tumor cells, with or without fresh frozen Bacillus Calmette-Guerin ('BCG') bacterial as an adjuvant.

Vaccinogen develops other programs in both active specific immunotherapy (vaccines) and passive specific immunotherapy (fully human monoclonal antibodies). Its HumaSPECT antibody was widely approved for any clinical use worldwide. The company develops other products based on pioneering work in colon carcinoma, renal carcinoma and melanoma.

Vaccinogen's partners include: Clinipace, Inc., Pro Concepta Zug Ag and INTRACEL Corp.